Selective Proteolysis of Human Type 2 Deiodinase: a Novel Ubiquitin-proteasomal Mediated Mechanism for Regulation of Hormone Activation
Overview
Molecular Biology
Affiliations
We investigated the mechanism by which T4 regulates its activation to T3 by the type 2 iodothyronine deiodinase (D2). D2 is a short- lived (t1/2 50 min), 31-kDa endoplasmic reticulum (ER) integral membrane selenoenzyme that generates intracellular T3. Inhibition of the ubiquitin (Ub) activating enzyme, E1, or MG132, a proteasome blocker, inhibits both the basal and substrate-induced acceleration of D2 degradation. Using a catalytically active transiently expressed FLAG-tagged-NH2-D2, we found rapid synthesis of high molecular mass (100-300 kDa) Ub-D2 conjugates that are catalytically inactive. Ub-D2 increases when cells are exposed to D2 substrate or MG132 and disappears rapidly after E1 inactivation. Fusion of FLAG epitope to the COOH terminus of D2 prolongs its half-life approximately 2.5-fold and increases the levels of active and, especially, Ub-D2. This indicates that COOH-terminal modification interferes with proteasomal uptake of Ub-D2 that can then be deubiquitinated. Interestingly, the type 1 deiodinase, a related selenoenzyme that also converts T4 to T3 but with a half-life of >12 h, is inactivated but not ubiquitinated or degraded after exposure to substrate. Thus, ubiquitination of the ER-resident enzyme D2 constitutes a specific posttranslational mechanism for T4 regulation of its own activation in the central nervous system and pituitary tissues in which D2-catalyzed T4 to T3 conversion is the major source of intracellular T3.
Variable transduction of thyroid hormone signaling in structures of the mouse brain.
Sinko R, Salas-Lucia F, Mohacsik P, Halmos E, Wittmann G, Egri P Proc Natl Acad Sci U S A. 2025; 122(6):e2415970122.
PMID: 39903117 PMC: 11831203. DOI: 10.1073/pnas.2415970122.
Metabolic Consequences of Thyroidectomy and Patient-Centered Management.
Wang K, Gulec S J Clin Med. 2024; 13(23).
PMID: 39685923 PMC: 11642069. DOI: 10.3390/jcm13237465.
Towell H, Braun D, Brol A, di Fonzo A, Rijntjes E, Kohrle J Biomolecules. 2024; 14(11).
PMID: 39595550 PMC: 11592359. DOI: 10.3390/biom14111373.
Treatment Preferences in Patients With Hypothyroidism.
de Lima Beltrao F, Carvalhal G, de Almeida Beltrao D, de Lima Beltrao F, de Lima Beltrao F, Ribeiro M J Clin Endocrinol Metab. 2024; 110(3):887-900.
PMID: 39290156 PMC: 11834714. DOI: 10.1210/clinem/dgae651.
Thyroid Hormone Homeostasis in Levothyroxine-treated Patients: Findings From ELSA-Brasil.
Penna G, Bensenor I, Bianco A, Ettleson M J Clin Endocrinol Metab. 2024; 109(10):2504-2512.
PMID: 38506164 PMC: 11403308. DOI: 10.1210/clinem/dgae139.